Company profile: Skyepharma
1.1 - Company Overview
Company description
- Provider of specialty drug delivery using oral and inhalation technologies to create enhanced versions of existing pharmaceutical products and products with new chemical entities. Offers Geomatrix modified-release tablets, stick-pack unit-dose packaging, serialization and aggregation, formulation development, and cGMP clinical trial manufacturing.
Products and services
- Clinical Trial Manufacturing: Produces clinical trial materials in cGMP-compliant facilities, with regulatory support during clinical phases to align manufacturing and compliance requirements
- Formulation Development: Architects complex oral solid dosage forms through scale-up-focused prototyping and up-scaling processes that transition laboratory formulations into progressively larger manufactured batches
- Geomatrix Technology: A patented drug delivery system used for the production of modified-release tablets, engineered by SkyePharma to fabricate modified-release pharmaceutical dosage forms.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Skyepharma
Navitor Pharmaceuticals
HQ: United States
Website
- Description: Provider of novel medicines targeting nutrient-sensing proteins, including NV-5138, an orally bioavailable small molecule that directly activates mTORC1 for treatment-resistant depression, and AT-20494, a selective mTORC1 inhibitor for autosomal dominant polycystic kidney disease and potentially other conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Navitor Pharmaceuticals company profile →
Sirtris Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on discovering and developing proprietary, orally available small molecule drugs to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirtris Pharmaceuticals company profile →
Xbrane Biopharma
HQ: Sweden
Website
- Description: Provider of complex generic biopharmaceuticals and novel bacterial protein expression technologies, with expertise in slow-release formulations. Products include Ximluci, a biosimilar of ranibizumab (Lucentis) for eye diseases, and Spherotide, a biosimilar of Decapeptyl primarily for prostate cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Xbrane Biopharma company profile →
Questcor Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical treatments for serious, difficult-to-treat autoimmune and inflammatory disorders, focused on neurology and nephrology, and supporting research efforts in a variety of conditions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Questcor Pharmaceuticals company profile →
Orbis Biosciences
HQ: United States
Website
- Description: Provider of scalable materials encapsulation solutions, enabling precise control of particle size, encapsulation material, shell thickness, and porosity for applications in drug formulations, agricultural compounds, and novel food processing techniques.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Orbis Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Skyepharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Skyepharma
2.2 - Growth funds investing in similar companies to Skyepharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Skyepharma
4.2 - Public trading comparable groups for Skyepharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →